UnknownPHASE2, PHASE3NCT05279365

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
DHR Health Institute for Research and Development
Principal Investigator
Sohail Rao, MD,MA,DPhil
DHR Health Institute for Research and Development
Intervention
Pfizer/BioNTech (BNT162b2)(biological)
Enrollment
1000 target
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05279365 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials